Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.51 |
| ▸ | CA1 | P00915 | 2/20 | 0.51 |
| ▸ | CA2 | P00918 | 2/20 | 0.51 |
| ▸ | CA9 | Q16790 | 2/20 | 0.51 |
| ▸ | CA5A | P35218 | 1/20 | 0.51 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.40 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.40 |
| ▸ | NQO2 | P16083 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2093102 | 0.83 | CA12 (0.73) | CA12CA1CA2CA9CA5A | |
| SCHEMBL3321085 | 0.83 | KMT2A (0.53) | ALDH1A1SMN1; SMN2POLBMEN1KMT2A | |
| SCHEMBL5991959 | 0.78 | GRIA4 (0.63) | CA12CA1CA2CA9CA5A | |
| SCHEMBL660035 | 0.77 | ALDH1A1 (0.68) | CA12CA1CA2CA9CA5A | |
| SCHEMBL1265707 | 0.76 | GRIA4 (0.69) | CA1CA2ALDH1A1SMN1; SMN2POLB | |
| SCHEMBL6788476 | 0.75 | TAAR1 (0.57) | CA12CA1CA2CA9CA5A | |
| SCHEMBL4887431 | 0.75 | CA1 (0.58) | CA12CA1CA2CA9CA5A | |
| SCHEMBL1267234 | 0.75 | MEN1 (0.57) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL5993697 | 0.75 | POLB (0.53) | CA12CA1CA2CA9CA5A | |
| SCHEMBL11340894 | 0.75 | TBXA2R (0.69) | CA12CA1CA2CA9CA5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6984756-B2 | Process for preparing biphenyl compounds | ELI LILLY AND COMPANY (US) | 2006-01-10 | — | — | US | disclosed |
| EP-1294683-B1 | A PROCESS FOR PREPARING BIPHENYL COMPOUNDS | LILLY CO ELI (US) | 2005-11-30 | — | — | EP | disclosed |
| US-6900353-B2 | Cyclopentyl sulfonamide derivatives | ELI LILLY AND COMPANY (US) | 2005-05-31 | — | — | US | disclosed |
| US-20040235957-A1 | Use of sulfonamide derivatives as pharmaceuticals compounds | BLEAKMAN DAVID (US) | 2004-11-25 | — | — | US | disclosed |
| EP-1438036-A2 | USE OF SULFONAMIDE DERIVATIVES AS PHARMACEUTICALS COMPOUNDS | ELI LILLY AND COMPANY (US) | 2004-07-21 | — | — | EP | disclosed |
| US-20040067984-A1 | Cyclopentyl sulfonamide derivatives | CANTRELL BUDDY EUGENE (US) | 2004-04-08 | — | — | US | disclosed |
| EP-1390072-A2 | USE OF AN AMPA RECEPTOR POTENTIATOR FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF TYPE 2 DIABETES | ELI LILLY AND COMPANY (US) | 2004-02-25 | — | — | EP | disclosed |
| US-20030225163-A1 | Sulfonamide derivatives | ELI LILLY AND COMPANY | 2003-12-04 | — | — | US | disclosed |
| EP-1334087-A1 | CYCLOALKYLFLUOROSULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2003-08-13 | — | — | EP | disclosed |
| EP-1311474-A1 | SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2003-05-21 | — | — | EP | disclosed |
| US-20030092947-A1 | Process for preparing biphenyl compounds | GARDNER JOHN PAUL (US) | 2003-05-15 | — | — | US | disclosed |
| WO-2003032974-A2 | USE OF SULFONAMIDE DERIVATIVES AS PHARMACEUTICALS COMPOUNDS | ELI LILLY AND COMPANY (US) | 2003-04-24 | — | — | WO | disclosed |
| EP-1294683-A2 | A PROCESS FOR PREPARING BIPHENYL COMPOUNDS | ELI LILLY AND COMPANY (US) | 2003-03-26 | — | — | EP | disclosed |
| EP-1292311-A2 | COMBINATION THERAPY FOR THE TREATMENT OF DEPRESSION COMPRISING AN ANTIDEPRESSANT AND AN AMPA RECEPTOR POTENTIATOR | ELI LILLY AND COMPANY (US) | 2003-03-19 | — | — | EP | disclosed |
| WO-2002089848-A2 | USE OF AN AMPA RECEPTOR POTENTIATOR FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF TYPE 2 DIABETES | ELI LILLY AND COMPANY (US) | 2002-11-14 | — | — | WO | disclosed |
| WO-2002032858-A1 | CYCLOALKYLFLUOROSULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2002-04-25 | — | — | WO | disclosed |
| WO-2001089530-A2 | COMBINATION THERAPY FOR TREATMENT OF DEPRESSION COMPRISING AN ANTIDEPRESSANT AND AN AMPA RECEPTOR POTENTIATOR | ELI LILLY AND COMPANY (US) | 2001-11-29 | — | — | WO | disclosed |
| WO-2001089510-A2 | USE OF AN AMPA RECEPTOR POTENTIATOR FOR THE TREATMENT OF OBESITY | ELI LILLY AND COMPANY (US) | 2001-11-29 | — | — | WO | disclosed |
| WO-2001090055-A2 | A PROCESS FOR PREPARING BIPHENYL COMPOUNDS | ELI LILLY AND COMPANY (US) | 2001-11-29 | — | — | WO | disclosed |
| WO-2001090057-A1 | SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067984-A1 | Cyclopentyl sulfonamide derivatives | GRIN2A, GRIN1, GRIK5 | CA12 3830/4885CA1 624/4885CA2 1437/4885 |
| US-20030225163-A1 | Sulfonamide derivatives | GRIN1, SLC1A2, GRIN2A | CA12 1290/4885CA1 277/4885CA2 751/4885 |
| US-20030092947-A1 | Process for preparing biphenyl compounds | CYP1B1, CYP4B1, CYP2B6 | CA12 2855/4885CA1 4001/4885CA2 3522/4885 |
| US-20040235957-A1 | Use of sulfonamide derivatives as pharmaceuticals compounds | GABRE, SCN2A, SCN1A | CA12 1034/4885CA1 1076/4885CA2 416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.